Clinical Research Directory
Browse clinical research sites, groups, and studies.
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Sponsor: Beni-Suef University
Summary
Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04
Completion Date
2026-12
Last Updated
2026-04-17
Healthy Volunteers
No
Conditions
Interventions
OnabotulinumtoxinA
OnabotulinumtoxinA will be injected intramuscularly at standard PREEMPT injection sites for chronic migraine prophylaxis. Total dose per session: 155 units distributed across 31 sites.
Greater Occipital Nerve Block (GONB)
Injection of local anesthetic (2% lidocaine, 1-2 mL per side) around the greater occipital nerve at the occipital region. Procedure performed by trained neurologist
Locations (1)
Beni-Suef University Hospital
Al Fayyum, Egypt